ClinicalTrials.gg
Sign In

Drug

Tambotatug pelitecan clinical trials

Also written YL201.

studies test it
12
open now
8
in phase 3
5
first study started
2022

Keep track of what changes. Save the tambotatug pelitecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

YL201 for Injection
2
Tambotatug pelitecan
2

Development codes

YL201
9

Studies by the year they started

12 studies that test it; most in 2026 (5)

Studies that test tambotatug pelitecan, by start year
YearStudies
20221
20231
20244
20251
20265

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
6
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it.

Small Cell Lung Carcinoma
2
Nasopharyngeal Carcinoma
1
Pancreatic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1

Who runs them

Industry 11 · Other 1

MediLink Therapeutics (Suzhou) Co., Ltd. (11) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Often tested with

Tested in the same studies.

Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1)

Studies

Open first, then newest update. How each study uses tambotatug pelitecan is read from its arms, and is right about nine times in ten.

Testing it · 12

Given in every arm · 2 — tambotatug pelitecan is usual care beside what is tested

Codes

What other systems call tambotatug pelitecan · ClinicalTrials.gg INT015208

  • UNII (FDA) 66NNR5T69QTAMBOTATUG PELITECANOne source FDA
  • NCI Thesaurus C188794Tambotatug PelitecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.